Global Green, Inc. Announces Appointment of Konky Sotomayor, DVM as Chief Scientist

Pam Lagano, 727-480-3082

. (OTCBB:GOGC) today announced the appointment of Konky Sotomayor, DVM as Chief Scientist of the Company.

Dr. Sotomayor, the developer of , graduated with honors as a Doctor in Veterinary Medicine and Zootechny in the Veterinary Medicine Faculty from the State University of Guayaquil in Ecuador. He attended the prestigious Lantanisbruk Universitet in Uppsala, Sweden, renowned for their International Science Program. The program assists countries in strengthening their domestic research capacity within the chemical, physical and the mathematical sciences.

Dr. Sotomayor, a U.S. citizen, has worked in private laboratory-managing research and development positions since 1979 including being a principal of Nutritional Health Institute Laboratories, LLC (“NHIL”). NHIL is ’s research affiliate and majority shareholder. He has extensive experience in isolation of infectious disease agents and manufacturing of the corresponding vaccines.

“This appointment recognizes Dr. Sotomayor’s key role in developing our flagship product, He has both a strong background and an extensive track record in animal infectious disease research and laboratory diagnostics. Dr. Sotomayor has been responsible for the discovery of novel drugs and steering their development from basic science into clinical development. His experience and R&D leadership will be instrumental as we execute our core strategy and work to build a pipeline of high value drug discovery and development programs,” commented , Chairman and CEO.

Currently, Dr. Sotomayor will be responsible for research and development of vaccines to expand Global Green’s product portfolio. it was initiating advanced trials in quest of a salmonella-free egg. The purpose of the study is to determine how long a chicken can be protected against Salmonella after it begins laying eggs.

is a green pharmaceutical company committed to identifying technology platforms and commercializing products that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards. Salmogenics, the Company’s flagship product, was developed by Nutritional Health Institute Laboratories, LLC, a research affiliate and majority shareholder. The vaccine is currently in the final stage of the USDA approval process. For more information, visit .

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.